The Zhitong Finance App learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) entered the US stock market. As of press release, the stock had risen more than 14% to $20.53. Latigo is committed to developing non-opioid pain relievers targeting the Nav1.8 sodium ion channel. Its core drug candidate, LTG-001, is an oral NaV1.8 inhibitor mainly used to treat moderate to severe acute pain, including postoperative pain. This medication is designed to provide analgesic effects comparable to opioids while avoiding the risk of addiction. Nav1.8 is mainly expressed in peripheral pain sensory neurons. Its inhibitors do not act on the central nervous system and are therefore not addictive.
Zhitongcaijing · 1d ago
Share
Listen to the news
The Zhitong Finance App learned that on Friday, non-opioid painkiller developer Latigo Biotherapeutics (LTGO.US) entered the US stock market. As of press release, the stock had risen more than 14% to $20.53. Latigo is committed to developing non-opioid pain relievers targeting the Nav1.8 sodium ion channel. Its core drug candidate, LTG-001, is an oral NaV1.8 inhibitor mainly used to treat moderate to severe acute pain, including postoperative pain. This medication is designed to provide analgesic effects comparable to opioids while avoiding the risk of addiction. Nav1.8 is mainly expressed in peripheral pain sensory neurons. Its inhibitors do not act on the central nervous system and are therefore not addictive.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending